CompletedPhase 4ACTRN12605000596606

SAFETY AND EFFICACY OF AMBISOME VS CONVENTIONAL AMPHOTERICIN B IN THE TREATMENT OF PATIENTS WITH SUSPECTED OR CONFIRMED MYCOSIS

Sponsor

Dr. Michael Whitby (Princess Alexandra Hsp, QLD)

Enrollment

104 participants

Start Date

Apr 1, 2007

Study Type

Interventional

Conditions

Mycosis - an invasive fungal infections

Eligibility

Sex: Both males and females

Plain Language Summary

Simplified for easier understanding

This study compares two forms of amphotericin B, a medication used to treat serious fungal infections. It is open to adults who have been diagnosed with a systemic fungal infection. Participants would receive either the standard or a newer liposomal form of the drug while being closely monitored.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Systemic treatment of mycosis with either liposomal amphotericin B (AmBisome by Gilead Sciences) or conventional amphotericin B (Fungizone by Bristol-Myers Squibb). Treatment will be given for a minimum of 14 days. However, if the patient's condition deteriorates after 10 days of therapy, the patient will be switched to salvage therapy (AmBisome 5mg/kg/day). TOtal duration of therapy depends on the infection and the patient's condition.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12605000596606